On 27 October 2011, orphan designation (EU/3/11/920) was granted by the European Commission to OctreoPharm Sciences GmbH, Germany, for gallium (68Ga)-pasireotide tetraxetan for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.
Gallium (68Ga)-pasireotide tetraxetan
|Disease / condition||
Diagnosis of gastro-entero-pancreatic neuroendocrine tumours
|Date of decision||
|Orphan decision number||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.